Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 869-874, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heidtmann, H. H.
Right arrow Articles by Havemann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heidtmann, H. H.
Right arrow Articles by Havemann, K.

Clinical Chemistry, Vol 39, 869-874, Copyright © 1993 by American Association for Clinical Chemistry

Assay of complexed alpha 1-antichymotrypsin in plasma

HH Heidtmann and K Havemann
Division of Hematology/Oncology and Clinical Immunology, Philipps Universitat Marburg, Germany.

We introduce an assay to measure complexed alpha 1-antichymotrypsin in human plasma. The assay works on the principle that the target proteinase cathepsin G has a very high affinity to the surface of microtiter plates, even if these surfaces are blocked with albumin and Tween 20. alpha 1-Antichymotrypsin, when complexed to cathepsin G, is thus immobilized and can be detected with specific antibodies. The mean (SD) concentration of alpha 1-antichymotrypsin in 50 healthy individuals was 1.73 (0.58) nmol/L. The detection limit was 0.84 nmol/L. The results of the assay are linear to at least 14 nmol/L. We propose to use this assay for diseases in which increased turnover of alpha 1-antichymotrypsin or cathepsin G can be expected to clarify further the function of this enzyme-inhibitor system.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
L. Zhu, J. Leinonen, W.-M. Zhang, P. Finne, and U.-H. Stenman
Dual-Label Immunoassay for Simultaneous Measurement of Prostate-specific Antigen (PSA)-{alpha}1-Antichymotrypsin Complex Together with Free or Total PSA
Clin. Chem., January 1, 2003; 49(1): 97 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
G. G. Klee, M. K. Goodmanson, S. J. Jacobsen, C. Y.F. Young, J. A. Finlay, H. G. Rittenhouse, R. L. Wolfert, and D. J. Tindall
Highly Sensitive Automated Chemiluminometric Assay for Measuring Free Human Glandular Kallikrein-2
Clin. Chem., June 1, 1999; 45(6): 800 - 806.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.